Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment - APPLY-PNH

Suzuki Kazuyuki0 个研究点目标入组 91 人开始时间: 2021年2月9日最近更新: 2023年10月17日

试验速览

暂无简介。

•Male and female participants >= 18 years of age with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size >= 10%
•- Stable regimen of anti-C5 antibody treatment (either eculizumab or ravulizumab) for at least 6 months prior to randomization
•- Mean hemoglobin level <10 g/dL
•- Vaccination against Neisseria meningitidis infection is required prior to the start of treatment.
•- If not received previously, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given

•- Participants on a stable eculizumab dose but with a dosing interval of 11 days or less
•- Known or suspected hereditary complement deficiency at screening
•- History of hematopoietic stem cell transplantation
•- Patients with laboratory evidence of bone marrow failure (reticulocytes <100x10E9/L; platelets <30x10E9/L; neutrophils <500x10E6/L).
•- Active systemic bacterial, viral or fungal infection within 14 days prior to study drug administration
•- A history of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus.
•- Major concurrent comorbidities including but not limited to severe kidney disease (e.g., dialysis), advanced cardiac disease (e.g., NYHA class IV), severe pulmonary disease (e.g., severe pulmonary) hypertension (WHO class IV)), or hepatic disease (e.g., active hepatitis) that in the opinion of the investigator precludes participant's participation in the study.

发起方

Suzuki Kazuyuki